No Data
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
The Recent 5.3% Gain Must Have Brightened President Liangzhi Xie's Week, Sino Biological,Inc.'s (SZSE:301047) Most Bullish Insider
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Yiqiao Shenzhou (301047.SZ): Yiqiao Taizhou has been recognized as a high-tech enterprise.
Glory Financial reported on February 19 that Yiqiao Shenzhou (301047.SZ) announced that its wholly-owned subsidiary Yiqiao Shenzhou (Taizhou) Technology Co., Ltd. (abbreviated as "Yiqiao Taizhou") recently received the "High-tech Enterprise Certificate" issued jointly by the Jiangsu Provincial Department of Science and Technology, the Jiangsu Provincial Department of Finance, and the State Taxation Administration Jiangsu Provincial Taxation Bureau.
Yiqiao Shenzhou (301047.SZ): The company's products and services are mainly applied to support the research work of research Institutions and Biomedical companies, and are not formulated medicines, thus not used for clinical treatment.
On February 10, Gelonghui reported that Yiqiao Shenzhou (301047.SZ) stated on the investor interaction platform that the company possesses a globally leading influenza reagent research library, providing important research reagents and technical support for pharmaceutical companies and other clients. As of now, the company's influenza reagent library includes H1N1, H3N2, H5N1, and other subtype influenza viruses, covering seasonal flu, Bird Flu, and other categories. The company's products and services are primarily applied to support the research work of Institutions and Biomedical companies, not for drug formulation or clinical treatment.
Yiqiao Shenzhou (301047.SZ): The Suzhou subsidiary has launched new products such as salt-loving nucleases and linker enzymes.
On February 10, Gelonghui reported that Yiqiao Shenzhou (301047.SZ) stated on the investor interaction platform that its subsidiary in Suzhou has launched new products such as salt-loving nucleases and linkage enzymes. The analysis and testing service Business has successfully completed on-site audits for multiple clients and has started taking on various testing projects, with the Business steadily developing.
Are Poor Financial Prospects Dragging Down Sino Biological,Inc. (SZSE:301047 Stock?